• Revenue growth guidance: The company is targeting ₹1,000 crore in revenue by FY27 with 20% growth, with about 20% of that total expected to come from new product launches across ADHD, anesthetics, and CMO/CDMO opportunities.
• EBITDA margin outlook: Management expects to maintain EBITDA margins between 33% and 35%, supported by an 80% backward-integrated product portfolio that shields the business from margin pressures despite supply-chain disruptions deferring ₹10 to ₹15 crore of sales into Q1 FY27.
• GLP-1 formulation strategy: Rather than entering the crowded API space, the company is focusing on finished formulations—including novel tablets and generic injection tie-ups—from its Ambernath facility, with EU approval anticipated by the end of FY27.
• Contract and intermediate ramp-up: The DSM partnership is on track to reach peak annual revenues of ₹75 crore in FY27, while the new backward-integrated cardiovascular intermediate is expected to generate approximately ₹100 crore from an off-take of 150 to 200 tons.